CoChat

EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease

Open access
Fautrel, Bruno, Mitrovic, Stéphane, De Matteis, Arianna, Bindoli, Sara, Antón, Jordi, Belot, Alexandre, Bracaglia, Claudia, Constantin, Tamàs, Dagna, Lorenzo, Di Bartolo, Alessandro, Feist, Eugen, Foell, Dirk, Gattorno, Marco, Georgin-Lavialle, Sophie, Giacomelli, Roberto, Grom, Alexei A, Jamilloux, Yvan, Laskari, Katerina, Lazar, Calin, Minoia, Francesca, Nigrovic, Peter A, Oliveira Ramos, Filipa, Ozen, Seza, Quartier, Pierre, Ruscitti, Piero, Sag, Erdal, Savic, Sinisa, Truchetet, Marie-Elise, Vastert, Sebastiaan J, Wilhelmer, Tanita-Christina, Wouters, Carine, Carmona, Loreto, De Benedetti, Fabrizio · 2024 · Annals of the Rheumatic Diseases
Cited by 221

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD) are considered the same disease, but a common approach for diagnosis and management is still missing. Methods In May 2022, EULAR and PReS endorsed a proposal for a joint task force (TF) to develop recommendations for the diagnosis and management of sJIA and AOSD. The TF agreed during a first meeting to address four topics: similarity between sJIA and AOSD, diagnostic biomarkers, therapeutic targets and strategies and complications including macrophage activation syndrome (MAS). Systematic literature reviews were conducted accordingly. Results The TF based their recommendations on four overarching principles, highlighting notably that sJIA and AOSD are one disease, to be designated by one name, Still’s disease. Fourteen specific recommendations were issued. Two therapeutic targets were defined: clinically inactive disease (CID) and remission, that is, CID maintained for at least 6 months. The optimal therapeutic strategy relies on early use of interleukin (IL-1 or IL-6 inhibitors associated to short duration glucocorticoid (GC). MAS treatment should rely on high-dose GCs, IL-1 inhibitors, ciclosporin and interferon-γ inhibitors. A specific concern rose recently with cases of severe lung disease in children with Still’s disease, for which T cell directed immunosuppressant are suggested. The recommendations emphasised the key role of expert centres for difficult-to-treat patients. All overarching principles and recommendations were agreed by over 80% of the TF experts with a high level of agreement. Conclusion These recommendations are the first consensus for the diagnosis and management of children and adults with Still’s disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/ard-2024-225851

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Metadata

Authors
Fautrel, B., Mitrovic, S., De Matteis, A., Bindoli, S., Antón, J., Belot, A., Bracaglia, C., Constantin, T., Dagna, L., Di Bartolo, A., Feist, E., Foell, D., Gattorno, M., Georgin-Lavialle, S., Giacomelli, R., Grom, A. A., Jamilloux, Y., Laskari, K., Lazar, C., Minoia, F., Nigrovic, P. A., Oliveira Ramos, F., Ozen, S., Quartier, P., Ruscitti, P., Sag, E., Savic, S., Truchetet, M.-E., Vastert, S. J., Wilhelmer, T.-C., Wouters, C., Carmona, L., & De Benedetti, F.
Venue
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Published
2024-12
Volume
83
Issue
12
Pages
1614-1627
ISSN
0003-4967 (ISSN-L)
OpenAlex
W4402812299
Cited by
221
References
2
FWCI
59.45
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease. https://app.cochat.ai/papers/10.1136/ard-2024-225851
The paper
Fautrel, B., Mitrovic, S., De Matteis, A., Bindoli, S., Antón, J., Belot, A., Bracaglia, C., Constantin, T., Dagna, L., Di Bartolo, A., Feist, E., Foell, D., Gattorno, M., Georgin-Lavialle, S., Giacomelli, R., Grom, A. A., Jamilloux, Y., Laskari, K., Lazar, C., . . . De Benedetti, F. (2024). EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease. Annals of the Rheumatic Diseases. https://doi.org/10.1136/ard-2024-225851

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.